1 min read
BIOSpain 2025
Meet Veristat at BIOSpain, October 7 - 9, 2025
Veristat is excited to attend BIOSpain 2025, one of Europe’s largest...
Bold Thinking that Delivers Results for RNA Therapies
Current advances in RNA-based therapies hold substantial promise in treating and preventing many human diseases and disorders through curing the disease, rather than treating the symptomology like traditional therapeutics.
While many RNA therapeutics have made it to clinical trials, only a few have been approved. Veristat’s team of scientific-minded experts
have worked on over 60 RNA programs, including several approved
therapies. Our experience expands across the clinical development pathway in a broad range of therapeutic areas.
In this piece, learn how Veristat has supported some of our Biotech Sponsors in advancing their RNA therapeutics, including:
- A landmark RNA approval
- Navigating a full-service COVID-19 vaccine trial
- Ensuring a Successful Regulatory Agency Interaction
Meet Veristat. Learn More.
- Partner of Choice for Biologics
- Regulatory Considerations for Biosimilars Development in the US
- Marketing Application Support
- Full-Service Clinical Development Solutions
Get the Latest News
Categories
- Regulatory Consulting (126)
- Regulatory Submissions (121)
- Clinical Trial Regulations (111)
- COVID-19 (46)
- Strategic Consulting (35)
- Clinical Trials (24)
- Life At Veristat (21)
- Events (16)
- Oncology (14)
- Success Stories (13)
- Project Management (11)
- Decentralized Trials/Virtual Trials (9)
- Medical Writing (9)
- Clinical Operations/Monitoring (8)
- Full-Service (7)
- CMC (6)
- Data Management (5)
- Marketing Applications (5)
- Adaptive Design (4)
- Statistics and Programming (4)
- Biologics (3)
- Cell Gene and RNA (3)
- Biometrics (2)
- Natural History (2)
- Neurology/CNS (1)
- Rare Diseases (1)
2 min read
TOPRA Symposium 2025
Sep 18, 2025 Veristat Events
Meet Veristat at the TOPRA Annual Symposium
Veristat is proud to attend the TOPRA Annual Symposium 2025, the leading...